Rare Disease Clinical Trials Market Size, Share | Report 2022-2030
Industry Insights
The global market for rare disease clinical trials is anticipated to register significant growth over the forecast period. The main driving factors of the rare disease clinical trial market are the increasing prevalence of rare diseases, which has led to rising research, intermittent launches, and a large number of products in the pipeline. Also, government initiatives that encourage product development, such as the Orphan Drug Act, are anticipated to assist industry growth.
The COVID-19 pandemic has greatly impacted our ability to conduct clinical trials. Due to the pandemic, various clinical trials of rare diseases were halted and delayed, and participant enrollment was postponed. This resulted in the delayed arrival of new treatments and drugs developed for the treatment of rare diseases. However, clinical trials for rare diseases resumed by the second half of 2020, and effective treatment and drugs for them were initiated.
Genetic disorders dominated the market in terms of therapeutic areas. This is due to the large number of rare diseases that are hereditary or arise due to genetic mutations. Genetic disorders encompass a wide range of diseases, including spinal muscular atrophy and cystic fibrosis.
The North America region is expected to dominate the market over the forecast period due to the presence of major market players offering rare disease clinical trials, and the increasing prevalence of disease, which will increase the demand for drugs that will in turn increase clinical trials for drug development, and the R&D expenditures made by market players for the creation of novel therapeutics for rare diseases. According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases, and they affect nearly 30 million Americans, or 1 in every 10 people.
The key market players include Takeda Pharmaceutical Company, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Novartis AG, LabCorp Drug Development, IQVIA, Charles River Laboratories Inc., Icon PLC, and Parexel International Corporation. They are adopting various strategies like partnerships, collaboration, merger and acquisition, and expansion. For instance, In January 2022, Pfizer announced a collaboration with Beam Therapeutics Inc. to research in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle, and central nervous system.
Market Segmentation
By Therapeutic Area Outlook
By Phase Outlook
By Sponsor Outlook
By Regional Outlook
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Rare Disease Clinical Trials Market
5.1. COVID-19 Landscape: Rare Disease Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Rare Disease Clinical Trials Market, By Therapeutic Area
8.1. Rare Disease Clinical Trials Market, by Therapeutic Area, 2022-2030
8.1.1 Oncology
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Cardiovascular Disorders
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Neurological Disorders
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Infectious Disease
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Genetic Disorders
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Autoimmune and Inflammation
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Hematologic Disorders
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Musculoskeletal Disorders
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Others
8.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Rare Disease Clinical Trials Market, By Phase
9.1. Rare Disease Clinical Trials Market, by Phase, 2022-2030
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Rare Disease Clinical Trials Market, By Sponsor
10.1. Rare Disease Clinical Trials Market, by Sponsor, 2022-2030
10.1.1. Pharmaceutical & Biopharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Non Profit Organizations
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Rare Disease Clinical Trials Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.1.2. Market Revenue and Forecast, by Phase (2017-2030)
11.1.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Phase (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Phase (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.2.2. Market Revenue and Forecast, by Phase (2017-2030)
11.2.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Phase (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Phase (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Phase (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Phase (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.3.2. Market Revenue and Forecast, by Phase (2017-2030)
11.3.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Phase (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Phase (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Phase (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Phase (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.4.2. Market Revenue and Forecast, by Phase (2017-2030)
11.4.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Phase (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Phase (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Phase (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Phase (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.5.2. Market Revenue and Forecast, by Phase (2017-2030)
11.5.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Phase (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Sponsor (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Phase (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Sponsor (2017-2030)
Chapter 12. Company Profiles
12.1. Takeda Pharmaceutical Company
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. LabCorp Drug Development
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. IQVIA
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Charles River Laboratories Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Icon PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Parexel International Corporation.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers